L-DOS47 Phase II Randomized Study Advances to Second Cohort

L-DOS47 Phase II Randomized Study Advances to Second Cohort RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee (“TSC”) reviewed safety data from the first dosing cohort of the Company’s LDOS003 study. No serious adverse events or dose limiting toxicities were observed. TSC recommended that Helix begin enrollment of patients into the second dosing cohort. 20190430-HBP-Press-Release-LDOS003-Second-Cohort.pdf

The release as fetched from its publisher. helixbiopharma.com ↗